Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata.…
Dermatology
-
-
MoonLake’s IL-17 inhibitor falls short of Bimzelx in HS trial
MoonLake Immunotherapeutics’s stock has crashed after its hidradenitis suppurativa (HS) candidate did not beat UCB’s Bimzelx (bimekizumab-bkz) in a pair…
-
J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu
Johnson & Johnson (J&J) and Protagonist Therapeutics’ icotrokinra has outperformed BMS’s Sotyktu (deucravacitinib) in treating patients with moderate-to-severe plaque psoriasis.…
-
EADV 25: Sanofi’s brivekimig success in Phase IIa HS trial
Sanofi’s brivekimig met the primary endpoint in a Phase IIa trial in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa…
-
Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial
Amgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational T-cell rebalancing…
-
Novartis culls ianalumab in HS after Phase IIb trial failure
Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet…
-
LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial
LEO Pharma has reported positive outcomes from the 16-week interim analysis of the randomised Phase IIIb ADHAND trial of fully…
-
Nektar’s stock doubles on eczema therapy success in Phase IIb study
Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin (rezpeg)…
-
Galderma shares new interim analysis data from trial for prurigo nodularis
Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment…
-
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis
US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for…
